Savara Inc., a clinical-stage biopharmaceutical company, reported a net loss of $26.6 million for the first quarter of 2025, compared to a net loss of $20.3 million in the same period of 2024. Research and development expenses increased by 14.0%, amounting to $19.2 million, up from $16.8 million in the first quarter of 2024. This increase was primarily attributed to activities related to the MOLBREEVI program, including $2.3 million for regulatory affairs and quality assurance. General and administrative expenses rose by 64.1% to $9.2 million for the three months ended March 31, 2025, from $5.6 million in the corresponding period of the previous year. This increase was driven by personnel and related costs of $2.4 million, commercial activities of $0.8 million, and departmental overhead of $0.4 million. As of March 31, 2025, Savara reported cash, cash equivalents, and short-term investments totaling approximately $172.5 million, with the company indicating that it is sufficiently capitalized into the second half of 2027. Additionally, the company carried a debt of approximately $29.5 million. Significant business updates include the completed submission of the Biologics License Application $(BLA.AU)$ to the U.S. Food and Drug Administration for MOLBREEVI, requesting priority review. Savara anticipates a potential U.S. commercial launch by early 2026, pending approval. The company also plans to submit the MOLBREEVI Marketing Authorization Application $(MAA)$ to the European Medicines Agency and the Medicines and Healthcare Products Regulatory Agency by the end of the year. Furthermore, Savara entered into a non-dilutive debt financing arrangement of up to $200 million in March, which included $30 million at close to refinance an existing debt facility.